Abcam Plc (ABCZY) 10.2500 $ABCZY Epigenetics Ma
Post# of 273250
Posted On: 07/01/2016 7:08:50 PM
Abcam Plc (ABCZY) 10.2500 $ABCZY
Epigenetics Market - Global Forecast to 2020 - Increasing Research Activities & High Prevalence of Cancer Driving Growth
M2 - Fri Feb 05, 8:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbv3tz/epigenetics) has announced the addition of the "Epigenetics Market - Global Forecast to 2020" report to their offering. The epigenetics market is expected to reach USD 890.0 Million by 2020 from USD 469.6 Million in 2015, at a CAGR of 13.64% between 2015 and 2020. Increasing research activities by academic and research institutes and high prevalence of cancer will majorly drive the growth of the market. Other growth factors include the increasing application for non-oncology diseases; and growing partnership between academic, biotechnology and pharmaceutical companies. The new emerging markets such as Brazil, Russia, India and China will provide opportunities for market growth. In 2015, the North America is expected to command the largest share of the global epigenetics market. Asia is expected to register the highest growth due to high prevalence of cancer, increasing research activities by various research institutes and increasing R & D funding by biotechnology and pharmaceutical companies in this region. Companies Mentioned: - Abcam PLC - Active Motif - Diagenode, Inc. - Illumina, Inc. - Merck & Co., Inc. - New England Biolabs - Qiagen N.V. - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. - Zymo Research Corporation Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Epigenetics Market, By Product 7 Epigenetics Market, By Research Area 8 Epigenetics Market, By Region 9 Competitive Landscape 10 Company Profiles For more information visit http://www.researchandmarkets.com/research/cb...pigenetics
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), ILMN: 140.73 (+0.35), QGEN: 22.10 (+0.29)
Global Prenatal & Maternal Diagnostic Market Analysis Report 2016 - Outlook to 2020
M2 - Wed Jan 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/gq559z/global_prenatal) has announced the addition of the "Global Prenatal & Maternal Diagnostic Market Analysis to 2020" report to their offering. A newly published analysis indicates that by 2021, the global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today. This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%. The new report, entitled GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021. This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis. When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and preimplantation genetic diagnosis (PGD) tests (prior to in vitro fertilization). In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cffDNA from maternal blood. The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos. The global prenatal and maternal diagnostic test market is assessed with respect to: - Fetal Ultrasound - Prenatal MRI Screening - Maternal Serum Screening Tests - Noninvasive Prenatal Tests (NIPTs) using cffDNA - NIPTs by Product - Prenatal Diagnostic Invasive Tests - Newborn Screening for Genetic Diseases - Newborn Screening Market by Technology - Preimplantation Screening/Diagnosis (PGS/PGD) SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets. Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries: - Molecular Diagnostics Market - Liquid Biopsy Market - Personalized Medicine Diagnostics Market - In vitro Diagnostics (IVD) Market Key Topics Covered: 1.0 Introduction 2.0 Prenatal Pregnancy Complications: An Overview 3.0 Types of Genetic Diseases in Fetuses: An Overview 4.0 Genetic Counseling: An Overview 5.0 Prenatal Screening for Genetic Diseases: An Overview 6.0 Newborn Screening 7.0 Preimplantation Genetic Screening & Genetic Diagnosis (PGS/PGD) 8.0 Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview 9.0 Prenatal Screening and Diagnostics: Market Overview 10.0 Other Genetic Testing-Related Markets 11.0 Market SWOT and Strategy Analysis 12.0 Company Profiles - 30 of the 114 Companies Featured in this Extensive Report - - 23andMe Inc. - - Abbott Laboratories - - Abbott Molecular Inc. - - Abcam plc - - AB Sciex LLC - - Adaltis S.r.l - - Adaptive Biotechnologies Corp. - - Affymetrix Inc. - - Agena Biosciences Inc. - - Agilent Technologies Inc. - - Ambry Genetics Corp. - - Analogic Corp. - - Ariosa Diagnostics Inc. - - Ansh Labs - - Appistry Inc. - - ARUP Laboratories - - AssureRx Health Inc. - - Asuragen Inc. - - Athena Diagnostics Inc. - - AutoGenomics Inc. - - Base4 Innovation Ltd. - - Beckman Coulter Inc. - - Berry Genomics Co., Ltd. - - Bina Technologies Inc. - - Bio-Rad (Israel) Laboratories Inc. - - BGI - - Blueprint Genetics Oy - - Boreal Genomics Inc. - - Cambridge Epigenetix Ltd. - - Claris Lifesciences For more information visit http://www.researchandmarkets.com/research/gq...l_prenatal
ABT: 39.54 (+0.23), AGMX: (), A: 44.60 (+0.24), ALOG: 80.57 (+1.13), AFFX: 14.01 (+0.02), ATHN: 138.14 (+0.13)
Leading 200 Global Small/Mid Cap Medical Devices/Technology/Supplies Companies
M2 - Thu Oct 22, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5zdn4/global_smallmid) has announced the addition of the "Global Small/Mid Cap Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Small/Mid cap medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information and stock market analysis. The health care sector is expanding as more individuals obtain health insurance yet the investment opportunities are shrinking in market cap. Expected government cuts to Medicare and Medicaid, the uncertainty of health care reform and looming patent expirations are weighing heavily on the outlook of the biggest companies in the sector - large-cap stocks. Stunning growth opportunities are found among mid-cap and small cap companies where one to three key products are driving performance. Their size makes them easier to follow and their above-average growth rates make them attractive acquisition targets in a consolidating industry. The median top line growth rate among large-cap companies is at 4%, while that in mid-cap companies is about 7% and that in all the small caps is more than 10%. When we look at a sample of the best in small-cap companies, we are looking at 40% growth. The primary reason large-cap companies don't have small-cap-type growth is that, over the last 20 years, the larger caps have acquired or developed devices in sectors that have been penetrated at significantly higher rates than newer sectors. Revenue growth and gross margin expansion are key factors to consider when valuing a medical device company and, especially, a small- to mid-cap medical device company. Highlights - Leading 200 Global Small/Mid Cap medical devices/technology/supplies companies covered - Provides detailed research methodology for deriving the leading 200 Small/Mid Cap companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Small/Mid Cap medical devices/technology/supplies companies - International presence of Global Small/Mid Cap medical devices/technology/supplies companies - Key R&D activities by Global Small/Mid Cap medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Global Small/Mid Cap Medical Devices/Technology/Supplies Companies with Most Increases 3: Key News of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 5: International Presence of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 6: Research and Development Activities by Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - AS One Corporation - Abcam Plc - Advanced Medical Solutions Group PLC - Agfa-Gevaert NV - Ambu A/S - Analogic Corp - Asia Optical Company Incorporated - Capitol Health Ltd - Cellectis SA - Coherent Incorporated - Conmed Corporation - Ebos Group Limited - Ginko International Co Ltd - Gooch & Housego PLC - Greatbatch, Inc. - Hartalega Holdings Bhd - Hogy Medical Company Limited - I - Sens Inc - Icu Medical, Inc. - Ilex Medical Limited - Jeol Limited - Natus Medical, Incorporation - Nolato AB - Novadaq Technologies Inc - Omnicell, Inc. - Sorin SpA - Sun Hing Vision Group Holdings Limited - Sunny Optical Technology (Group) Company Limited - Tamron Co Ltd - Tecan Group AG - Thai Optical Group Public Company Limited - Tornier NV - Value Added Technology Co., Limited. - Vitrolife AB - Wonik Company Limited For more information visit http://www.researchandmarkets.com/research/s5...l_smallmid
ALOG: 80.57 (+1.13), GB: 30.93 (+0.63), TRNX: 20.67 (+0.28), BABY: 37.81 (+0.01), CLLS: 27.25 (+0.66), COHR: 90.50 (-1.28), OMCL: 35.73 (+1.50), NVDQ: 9.98 (+0.14)
Leading 200 Global Medical Devices/Technology/Supplies Company Analysis 2015 - News, Financial/Non-Financial Information, and Stock Market Analysis
M2 - Wed Oct 21, 2:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5th588/global_most) has announced the addition of the "Global Most International Medical Devices/Technology/Supplies 200 " report to their offering. This newly launched report identifies 200 Most International medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. In today's rapidly changing business climate, understanding the regulatory and demographic environment of the medical industry is only part of the challenge. The real struggle for medical device companies is defining the right strategy, particularly with increasing consolidation, heightened regulation, and shifting market demands. Firms that are able to adapt quickly, taking advantage of the transformative nature of the industry, will become inherent market leaders. There are many companies in the medical devices/technology/supplies industry that have presence in many countries worldwide. Since last few years, these companies have established and expanded their presence in global markets. Such companies are dedicated to improving people's health throughout the world. These companies have global marketing and sales capabilities with a presence in many countries worldwide. Highlights - Leading 200 Most Global medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Most Global medical devices/technology/supplies companies - International presence of Most Global medical devices/technology/supplies companies - Key R&D activities by Most Global medical devices/technology/supplies companies Key Topics Covered: nalysis Section: 1: Rankings of Most Global Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Most Global Medical Devices/Technology/Supplies Companies with Most Increases News Section: 3: Key News of Most Global Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Most Global Medical Devices/Technology/Supplies Companies 5: Research and Development Activities by Most Global Medical Devices/Technology/Supplies Companies 6: International Presence of Most Global Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Most Global Medical Devices/Technology/Supplies Companies Sample list of company names included in this industry report: - 3 D Matrix Ltd (Japan) - 3M Company (United States) - aap Implantate AG (Germany) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Accuray Inc (United States) - Alphatec Holdings, Inc. (United States) - Ambu A/S (Denmark) - Amplifon SpA (Italy) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - Carl Zeiss Meditec AG (Germany) - Cepheid (United States) - Cochlear Limited (Australia) - Coherent Incorporated (United States) - Draegerwerk AG & Co KGaA (Germany) - Fresenius Medical Care AG & Co. KGaA (Germany) - Hitachi High Technologies Corp (Japan) - Impedimed Limited (Australia) - Masimo Corporation (United States) - Nitto Denko (Japan) - Osim International Limited (Singapore) - Sonova Holding AG (Switzerland) - Stratec Biomedical AG (Germany) - Zimmer Holdings, Inc. (United States) For more information visit http://www.researchandmarkets.com/research/5t...lobal_most
ZMH: 113.56 (+0.29), MMM: 175.54 (+0.42), ATEC: 0.42 (+0.07), MASI: 52.47 (-0.04), ARAY: 5.11 (-0.08), BSX: 23.41 (+0.04), ABAX: 48.35 (+1.12), BAX: 45.45 (+0.23), CPHD: 33.19 (+2.44), COHR: 90.50 (-1.28)
200 Most Diversified Medical Devices/Technology/Supplies Companies Globally
M2 - Tue Oct 20, 6:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx7zxr/global_most) has announced the addition of the "Global Most Diversified Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Most Diversified medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. The global medical device sector is a highly diversified and export-oriented industry that manufactures medical equipments as well as supplies. The purchasers for the same include hospitals, physician's offices, laboratories, clinics as well as patients (through direct purchases). The sector is populated with companies driven by product innovation. The industry is able to draw on world-class innovative research being conducted in global universities, research institutes, and hospitals, some of which has been spun-off into global medical device companies. Big, highly diversified medical technology companies are tapping into health-care spending spikes in emerging countries. That's in contrast to a U.S. market for medical devices that is mature and slow growing. Emerging market countries have large, aging populations and rising incomes, which equates to 15 percent revenue growth for medical technology companies from those countries. The medical devices/technology sector has become increasingly dominated by larger, diversified companies such as Medtronic, Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Guidant Corporation, Stryker Corporation, Zimmer Medical Holdings, Vasomedical, Inc., Integra LifeSciences Holdings Corporation, and many more. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the Most Diversified companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Highlights - Leading 200 Global Most Diversified medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Most Diversified medical devices/technology/supplies companies - International presence of Global Most Diversified medical devices/technology/supplies companies - Key R&D activities by Global Most Diversified medical devices/technology/supplies companies Sample list of company names included in this industry report: - 3D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/lx...lobal_most
ATEC: 0.42 (+0.07), GBSNU: 16.22 (-0.28), MZOR: 18.32 (+0.34), FEIC: 107.01 (+0.13), BSX: 23.41 (+0.04), JNJ: 121.29 (-0.01), ZLTQ: 27.63 (+0.30), IARTV: 65.00 (-37.45), STJ: 78.24 (+0.24), BVX: 1.70 (+0.06), SYK: 120.41 (+0.58)
Abcam's New Anti-PD-L1 Antibody Enables Deeper Insights into Cancer Immunology Research
BusinessWire - Tue Oct 06, 5:12AM CDT
Abcam plc, a global leader in the supply of life sciences research tools, today announced the launch of its anti-PD-L1 primary antibody (clone 28-
. Produced using Abcam's RabMAb(R) recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research.
ABC: 80.16 (+0.84)
G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Fri Jul 17, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h8sv7h/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTP?S binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter's Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd. The global GPCRs market is segmented as follows: GPCRs Market, by Assay Type - Calcium Level Detection Assays - GTPyS Binding Assays - cGMP Assays - Reporter Gene Assays - Receptor Internalization Assay - cAMP Assays GPCRs Market, by Therapeutic Area - Cardiovascular System - Central Nervous System - Respiratory System - Immune System - Reproductive System - Oncology - Others For more information visit http://www.researchandmarkets.com/research/h8...in_coupled
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), QGEN: 22.10 (+0.29), PKI: 52.66 (+0.24)
Oxidative Stress Assay Market by Product, Test Type, Technology, End Users - Global Forecast to 2020
M2 - Fri May 29, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8b9r9d/oxidative_stress) has announced the addition of the "Oxidative Stress Assay Market by Product (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology (ELISA, Chromatography, Flow Cytometry), End Users - Global Forecast to 2020" report to their offering. The global oxidative stress assay market is expected to reach $736.85 Million by 2020 from $452.36 Million in 2015, growing at a CAGR of 10.25% from 2015 to 2020 Oxidative stress assays is a well-established method for screening and detecting markers of oxidative stress in cultured cells. The assay kits gives more relevant biological information compared to that obtained by the measurement of individual components, hence it is a great tool for evaluating the capacity to counter oxidative stress. With rapid innovations in oxidative stress assays technologies, researchers are now able to detect oxidative stress biomarkers very easily. Furthermore, with rapid developments in the field of oxidative stress assays, researchers are equipped with new technological advances to generate high accuracy and efficiency in the testing of oxidative stress. The report provides a granular understanding of the oxidative stress assay market. This report segments the global oxidative stress assay market on the basis of products, test types, technologies, end users, and regions. The product segments included in this report are consumables, instruments, and services. On the basis of test types, the market is segmented into indirect assays, antioxidant capacity assays, enzyme-based assays, and reactive oxygen species (ROS)-based assays. The end-user segments included in this report are pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and contract research organizations. The report maps each test type and product segment in 11 geographic and regional segments. The major players in the oxidative stress assay market include Abcam plc (U.K.), AMS Biotechnology (U.K.), BioVision, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Enzo Biochem (U.S.), Merck and Co., Inc. (U.S.), Oxford Biomedical Research (U.S.), QIAGEN N.V. (Netherlands), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Oxidative Stress Assays Market, By Product 8 Oxidative Stress Assays Market, By Technology 9 Oxidative Stress Assays Market, By Test Type 10 Oxidative Stress Assays Market, By End User 11 Oxidative Stress Assays Market, By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/8b...ive_stress
ENZ: 5.97 (unch), SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), QGEN: 22.10 (+0.29)
Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019
M2 - Mon May 18, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49qvgs/antibody) has announced the addition of the "Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019" report to their offering. The global antibody production market is expected to reach $2.572 Billion in 2019 from $1.425 Billion in 2014, growing at a CAGR of 12.5%. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the fastest rate during the forecast period. Antibodies, also known as immunoglobulins, are specialized immune proteins produced when an antigen enters the body. Antibodies are produced by the immune system in response to the presence of foreign antigens or targets such as viruses and bacteria. Antibodies can be produced using hybridoma and hybridoma-free techniques. The major types of antibodies produced are monoclonal and polyclonal antibodies. The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions. By product, this market is categorized into equipment and consumables. In 2014, the consumables segment accounted for the largest share of this market. This segment is expected to grow at the fastest rate during the forecast period (2014 to 2019). On the basis of type, this market is divided into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for the largest share of the market. However, the polyclonal antibodies segment is expected to grow at the fastest rate during the forecast period. The globa market, by technology, is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for the largest share of the market. However, the hybridoma-free technology segment is expected to grow at the fastest rate during the forecast period. This market, by end user, is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. The biotechnology and pharmaceutical companies segment is the largest and fastest-growing segment of the antibody production market. The key factors that are expected to spur the growth of this market are increasing demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market. Some of the major players in the global market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany). For more information visit http://www.researchandmarkets.com/research/49qvgs/antibody
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), AMGN: 154.28 (+2.13)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 175.54 (+0.42), COO: 177.34 (+5.77), SNN: 34.56 (+0.24), VCYT: 5.02 (-0.01), ABAX: 48.35 (+1.12), DYSL: 1.42 (+0.10), VOLC: 17.99 (+0.01), CLLS: 27.25 (+0.66), COHR: 90.50 (-1.28), HRC: 50.75 (+0.30)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.42 (+0.07), GBSNU: 16.22 (-0.28), MZOR: 18.32 (+0.34), FEIC: 107.01 (+0.13), ZLTQ: 27.63 (+0.30), IART: 80.15 (+0.37), BVX: 1.70 (+0.06)
GeoSpock Limited Completes £782,500 ($1,245,350) Fundraising and Enters the TechStars Global Startup Accelerator
PR Newswire - Mon Nov 10, 3:47AM CST
UK geosearch tech firm raises cash to commercialise its GeoWarp(TM), Collide(TM) and Collide App Designer(TM) platforms that enable businesses wishing to take advantage of growing trends in the internet-of-things, big-data and multi-dimensional, real-time geospatial experiences.
ABC: 80.16 (+0.84)
Epigenetics Market - Global Forecast to 2020 - Increasing Research Activities & High Prevalence of Cancer Driving Growth
M2 - Fri Feb 05, 8:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbv3tz/epigenetics) has announced the addition of the "Epigenetics Market - Global Forecast to 2020" report to their offering. The epigenetics market is expected to reach USD 890.0 Million by 2020 from USD 469.6 Million in 2015, at a CAGR of 13.64% between 2015 and 2020. Increasing research activities by academic and research institutes and high prevalence of cancer will majorly drive the growth of the market. Other growth factors include the increasing application for non-oncology diseases; and growing partnership between academic, biotechnology and pharmaceutical companies. The new emerging markets such as Brazil, Russia, India and China will provide opportunities for market growth. In 2015, the North America is expected to command the largest share of the global epigenetics market. Asia is expected to register the highest growth due to high prevalence of cancer, increasing research activities by various research institutes and increasing R & D funding by biotechnology and pharmaceutical companies in this region. Companies Mentioned: - Abcam PLC - Active Motif - Diagenode, Inc. - Illumina, Inc. - Merck & Co., Inc. - New England Biolabs - Qiagen N.V. - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. - Zymo Research Corporation Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Epigenetics Market, By Product 7 Epigenetics Market, By Research Area 8 Epigenetics Market, By Region 9 Competitive Landscape 10 Company Profiles For more information visit http://www.researchandmarkets.com/research/cb...pigenetics
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), ILMN: 140.73 (+0.35), QGEN: 22.10 (+0.29)
Global Prenatal & Maternal Diagnostic Market Analysis Report 2016 - Outlook to 2020
M2 - Wed Jan 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/gq559z/global_prenatal) has announced the addition of the "Global Prenatal & Maternal Diagnostic Market Analysis to 2020" report to their offering. A newly published analysis indicates that by 2021, the global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today. This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%. The new report, entitled GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021. This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis. When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and preimplantation genetic diagnosis (PGD) tests (prior to in vitro fertilization). In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cffDNA from maternal blood. The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos. The global prenatal and maternal diagnostic test market is assessed with respect to: - Fetal Ultrasound - Prenatal MRI Screening - Maternal Serum Screening Tests - Noninvasive Prenatal Tests (NIPTs) using cffDNA - NIPTs by Product - Prenatal Diagnostic Invasive Tests - Newborn Screening for Genetic Diseases - Newborn Screening Market by Technology - Preimplantation Screening/Diagnosis (PGS/PGD) SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets. Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries: - Molecular Diagnostics Market - Liquid Biopsy Market - Personalized Medicine Diagnostics Market - In vitro Diagnostics (IVD) Market Key Topics Covered: 1.0 Introduction 2.0 Prenatal Pregnancy Complications: An Overview 3.0 Types of Genetic Diseases in Fetuses: An Overview 4.0 Genetic Counseling: An Overview 5.0 Prenatal Screening for Genetic Diseases: An Overview 6.0 Newborn Screening 7.0 Preimplantation Genetic Screening & Genetic Diagnosis (PGS/PGD) 8.0 Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview 9.0 Prenatal Screening and Diagnostics: Market Overview 10.0 Other Genetic Testing-Related Markets 11.0 Market SWOT and Strategy Analysis 12.0 Company Profiles - 30 of the 114 Companies Featured in this Extensive Report - - 23andMe Inc. - - Abbott Laboratories - - Abbott Molecular Inc. - - Abcam plc - - AB Sciex LLC - - Adaltis S.r.l - - Adaptive Biotechnologies Corp. - - Affymetrix Inc. - - Agena Biosciences Inc. - - Agilent Technologies Inc. - - Ambry Genetics Corp. - - Analogic Corp. - - Ariosa Diagnostics Inc. - - Ansh Labs - - Appistry Inc. - - ARUP Laboratories - - AssureRx Health Inc. - - Asuragen Inc. - - Athena Diagnostics Inc. - - AutoGenomics Inc. - - Base4 Innovation Ltd. - - Beckman Coulter Inc. - - Berry Genomics Co., Ltd. - - Bina Technologies Inc. - - Bio-Rad (Israel) Laboratories Inc. - - BGI - - Blueprint Genetics Oy - - Boreal Genomics Inc. - - Cambridge Epigenetix Ltd. - - Claris Lifesciences For more information visit http://www.researchandmarkets.com/research/gq...l_prenatal
ABT: 39.54 (+0.23), AGMX: (), A: 44.60 (+0.24), ALOG: 80.57 (+1.13), AFFX: 14.01 (+0.02), ATHN: 138.14 (+0.13)
Leading 200 Global Small/Mid Cap Medical Devices/Technology/Supplies Companies
M2 - Thu Oct 22, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5zdn4/global_smallmid) has announced the addition of the "Global Small/Mid Cap Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Small/Mid cap medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information and stock market analysis. The health care sector is expanding as more individuals obtain health insurance yet the investment opportunities are shrinking in market cap. Expected government cuts to Medicare and Medicaid, the uncertainty of health care reform and looming patent expirations are weighing heavily on the outlook of the biggest companies in the sector - large-cap stocks. Stunning growth opportunities are found among mid-cap and small cap companies where one to three key products are driving performance. Their size makes them easier to follow and their above-average growth rates make them attractive acquisition targets in a consolidating industry. The median top line growth rate among large-cap companies is at 4%, while that in mid-cap companies is about 7% and that in all the small caps is more than 10%. When we look at a sample of the best in small-cap companies, we are looking at 40% growth. The primary reason large-cap companies don't have small-cap-type growth is that, over the last 20 years, the larger caps have acquired or developed devices in sectors that have been penetrated at significantly higher rates than newer sectors. Revenue growth and gross margin expansion are key factors to consider when valuing a medical device company and, especially, a small- to mid-cap medical device company. Highlights - Leading 200 Global Small/Mid Cap medical devices/technology/supplies companies covered - Provides detailed research methodology for deriving the leading 200 Small/Mid Cap companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Small/Mid Cap medical devices/technology/supplies companies - International presence of Global Small/Mid Cap medical devices/technology/supplies companies - Key R&D activities by Global Small/Mid Cap medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Global Small/Mid Cap Medical Devices/Technology/Supplies Companies with Most Increases 3: Key News of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 5: International Presence of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 6: Research and Development Activities by Global Small/Mid Cap Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Global Small/Mid Cap Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - AS One Corporation - Abcam Plc - Advanced Medical Solutions Group PLC - Agfa-Gevaert NV - Ambu A/S - Analogic Corp - Asia Optical Company Incorporated - Capitol Health Ltd - Cellectis SA - Coherent Incorporated - Conmed Corporation - Ebos Group Limited - Ginko International Co Ltd - Gooch & Housego PLC - Greatbatch, Inc. - Hartalega Holdings Bhd - Hogy Medical Company Limited - I - Sens Inc - Icu Medical, Inc. - Ilex Medical Limited - Jeol Limited - Natus Medical, Incorporation - Nolato AB - Novadaq Technologies Inc - Omnicell, Inc. - Sorin SpA - Sun Hing Vision Group Holdings Limited - Sunny Optical Technology (Group) Company Limited - Tamron Co Ltd - Tecan Group AG - Thai Optical Group Public Company Limited - Tornier NV - Value Added Technology Co., Limited. - Vitrolife AB - Wonik Company Limited For more information visit http://www.researchandmarkets.com/research/s5...l_smallmid
ALOG: 80.57 (+1.13), GB: 30.93 (+0.63), TRNX: 20.67 (+0.28), BABY: 37.81 (+0.01), CLLS: 27.25 (+0.66), COHR: 90.50 (-1.28), OMCL: 35.73 (+1.50), NVDQ: 9.98 (+0.14)
Leading 200 Global Medical Devices/Technology/Supplies Company Analysis 2015 - News, Financial/Non-Financial Information, and Stock Market Analysis
M2 - Wed Oct 21, 2:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5th588/global_most) has announced the addition of the "Global Most International Medical Devices/Technology/Supplies 200 " report to their offering. This newly launched report identifies 200 Most International medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. In today's rapidly changing business climate, understanding the regulatory and demographic environment of the medical industry is only part of the challenge. The real struggle for medical device companies is defining the right strategy, particularly with increasing consolidation, heightened regulation, and shifting market demands. Firms that are able to adapt quickly, taking advantage of the transformative nature of the industry, will become inherent market leaders. There are many companies in the medical devices/technology/supplies industry that have presence in many countries worldwide. Since last few years, these companies have established and expanded their presence in global markets. Such companies are dedicated to improving people's health throughout the world. These companies have global marketing and sales capabilities with a presence in many countries worldwide. Highlights - Leading 200 Most Global medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Most Global medical devices/technology/supplies companies - International presence of Most Global medical devices/technology/supplies companies - Key R&D activities by Most Global medical devices/technology/supplies companies Key Topics Covered: nalysis Section: 1: Rankings of Most Global Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 12 Months: Leading 25 Most Global Medical Devices/Technology/Supplies Companies with Most Increases News Section: 3: Key News of Most Global Medical Devices/Technology/Supplies Companies for Year 2014-15 4: Key Alliances of Most Global Medical Devices/Technology/Supplies Companies 5: Research and Development Activities by Most Global Medical Devices/Technology/Supplies Companies 6: International Presence of Most Global Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of Most Global Medical Devices/Technology/Supplies Companies Sample list of company names included in this industry report: - 3 D Matrix Ltd (Japan) - 3M Company (United States) - aap Implantate AG (Germany) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Accuray Inc (United States) - Alphatec Holdings, Inc. (United States) - Ambu A/S (Denmark) - Amplifon SpA (Italy) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Baxter International Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Boston Scientific Corporation (United States) - Bruker Corporation (United States) - Carl Zeiss Meditec AG (Germany) - Cepheid (United States) - Cochlear Limited (Australia) - Coherent Incorporated (United States) - Draegerwerk AG & Co KGaA (Germany) - Fresenius Medical Care AG & Co. KGaA (Germany) - Hitachi High Technologies Corp (Japan) - Impedimed Limited (Australia) - Masimo Corporation (United States) - Nitto Denko (Japan) - Osim International Limited (Singapore) - Sonova Holding AG (Switzerland) - Stratec Biomedical AG (Germany) - Zimmer Holdings, Inc. (United States) For more information visit http://www.researchandmarkets.com/research/5t...lobal_most
ZMH: 113.56 (+0.29), MMM: 175.54 (+0.42), ATEC: 0.42 (+0.07), MASI: 52.47 (-0.04), ARAY: 5.11 (-0.08), BSX: 23.41 (+0.04), ABAX: 48.35 (+1.12), BAX: 45.45 (+0.23), CPHD: 33.19 (+2.44), COHR: 90.50 (-1.28)
200 Most Diversified Medical Devices/Technology/Supplies Companies Globally
M2 - Tue Oct 20, 6:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx7zxr/global_most) has announced the addition of the "Global Most Diversified Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Most Diversified medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. The global medical device sector is a highly diversified and export-oriented industry that manufactures medical equipments as well as supplies. The purchasers for the same include hospitals, physician's offices, laboratories, clinics as well as patients (through direct purchases). The sector is populated with companies driven by product innovation. The industry is able to draw on world-class innovative research being conducted in global universities, research institutes, and hospitals, some of which has been spun-off into global medical device companies. Big, highly diversified medical technology companies are tapping into health-care spending spikes in emerging countries. That's in contrast to a U.S. market for medical devices that is mature and slow growing. Emerging market countries have large, aging populations and rising incomes, which equates to 15 percent revenue growth for medical technology companies from those countries. The medical devices/technology sector has become increasingly dominated by larger, diversified companies such as Medtronic, Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Guidant Corporation, Stryker Corporation, Zimmer Medical Holdings, Vasomedical, Inc., Integra LifeSciences Holdings Corporation, and many more. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the Most Diversified companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Highlights - Leading 200 Global Most Diversified medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Most Diversified medical devices/technology/supplies companies - International presence of Global Most Diversified medical devices/technology/supplies companies - Key R&D activities by Global Most Diversified medical devices/technology/supplies companies Sample list of company names included in this industry report: - 3D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/lx...lobal_most
ATEC: 0.42 (+0.07), GBSNU: 16.22 (-0.28), MZOR: 18.32 (+0.34), FEIC: 107.01 (+0.13), BSX: 23.41 (+0.04), JNJ: 121.29 (-0.01), ZLTQ: 27.63 (+0.30), IARTV: 65.00 (-37.45), STJ: 78.24 (+0.24), BVX: 1.70 (+0.06), SYK: 120.41 (+0.58)
Abcam's New Anti-PD-L1 Antibody Enables Deeper Insights into Cancer Immunology Research
BusinessWire - Tue Oct 06, 5:12AM CDT
Abcam plc, a global leader in the supply of life sciences research tools, today announced the launch of its anti-PD-L1 primary antibody (clone 28-
. Produced using Abcam's RabMAb(R) recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research. ABC: 80.16 (+0.84)
G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Fri Jul 17, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h8sv7h/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTP?S binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter's Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd. The global GPCRs market is segmented as follows: GPCRs Market, by Assay Type - Calcium Level Detection Assays - GTPyS Binding Assays - cGMP Assays - Reporter Gene Assays - Receptor Internalization Assay - cAMP Assays GPCRs Market, by Therapeutic Area - Cardiovascular System - Central Nervous System - Respiratory System - Immune System - Reproductive System - Oncology - Others For more information visit http://www.researchandmarkets.com/research/h8...in_coupled
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), QGEN: 22.10 (+0.29), PKI: 52.66 (+0.24)
Oxidative Stress Assay Market by Product, Test Type, Technology, End Users - Global Forecast to 2020
M2 - Fri May 29, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8b9r9d/oxidative_stress) has announced the addition of the "Oxidative Stress Assay Market by Product (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology (ELISA, Chromatography, Flow Cytometry), End Users - Global Forecast to 2020" report to their offering. The global oxidative stress assay market is expected to reach $736.85 Million by 2020 from $452.36 Million in 2015, growing at a CAGR of 10.25% from 2015 to 2020 Oxidative stress assays is a well-established method for screening and detecting markers of oxidative stress in cultured cells. The assay kits gives more relevant biological information compared to that obtained by the measurement of individual components, hence it is a great tool for evaluating the capacity to counter oxidative stress. With rapid innovations in oxidative stress assays technologies, researchers are now able to detect oxidative stress biomarkers very easily. Furthermore, with rapid developments in the field of oxidative stress assays, researchers are equipped with new technological advances to generate high accuracy and efficiency in the testing of oxidative stress. The report provides a granular understanding of the oxidative stress assay market. This report segments the global oxidative stress assay market on the basis of products, test types, technologies, end users, and regions. The product segments included in this report are consumables, instruments, and services. On the basis of test types, the market is segmented into indirect assays, antioxidant capacity assays, enzyme-based assays, and reactive oxygen species (ROS)-based assays. The end-user segments included in this report are pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and contract research organizations. The report maps each test type and product segment in 11 geographic and regional segments. The major players in the oxidative stress assay market include Abcam plc (U.K.), AMS Biotechnology (U.K.), BioVision, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Enzo Biochem (U.S.), Merck and Co., Inc. (U.S.), Oxford Biomedical Research (U.S.), QIAGEN N.V. (Netherlands), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Oxidative Stress Assays Market, By Product 8 Oxidative Stress Assays Market, By Technology 9 Oxidative Stress Assays Market, By Test Type 10 Oxidative Stress Assays Market, By End User 11 Oxidative Stress Assays Market, By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/8b...ive_stress
ENZ: 5.97 (unch), SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), QGEN: 22.10 (+0.29)
Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019
M2 - Mon May 18, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49qvgs/antibody) has announced the addition of the "Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019" report to their offering. The global antibody production market is expected to reach $2.572 Billion in 2019 from $1.425 Billion in 2014, growing at a CAGR of 12.5%. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the fastest rate during the forecast period. Antibodies, also known as immunoglobulins, are specialized immune proteins produced when an antigen enters the body. Antibodies are produced by the immune system in response to the presence of foreign antigens or targets such as viruses and bacteria. Antibodies can be produced using hybridoma and hybridoma-free techniques. The major types of antibodies produced are monoclonal and polyclonal antibodies. The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions. By product, this market is categorized into equipment and consumables. In 2014, the consumables segment accounted for the largest share of this market. This segment is expected to grow at the fastest rate during the forecast period (2014 to 2019). On the basis of type, this market is divided into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for the largest share of the market. However, the polyclonal antibodies segment is expected to grow at the fastest rate during the forecast period. The globa market, by technology, is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for the largest share of the market. However, the hybridoma-free technology segment is expected to grow at the fastest rate during the forecast period. This market, by end user, is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. The biotechnology and pharmaceutical companies segment is the largest and fastest-growing segment of the antibody production market. The key factors that are expected to spur the growth of this market are increasing demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market. Some of the major players in the global market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany). For more information visit http://www.researchandmarkets.com/research/49qvgs/antibody
SIAL: 139.97 (+0.21), MRK: 57.94 (+0.33), AMGN: 154.28 (+2.13)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 175.54 (+0.42), COO: 177.34 (+5.77), SNN: 34.56 (+0.24), VCYT: 5.02 (-0.01), ABAX: 48.35 (+1.12), DYSL: 1.42 (+0.10), VOLC: 17.99 (+0.01), CLLS: 27.25 (+0.66), COHR: 90.50 (-1.28), HRC: 50.75 (+0.30)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.42 (+0.07), GBSNU: 16.22 (-0.28), MZOR: 18.32 (+0.34), FEIC: 107.01 (+0.13), ZLTQ: 27.63 (+0.30), IART: 80.15 (+0.37), BVX: 1.70 (+0.06)
GeoSpock Limited Completes £782,500 ($1,245,350) Fundraising and Enters the TechStars Global Startup Accelerator
PR Newswire - Mon Nov 10, 3:47AM CST
UK geosearch tech firm raises cash to commercialise its GeoWarp(TM), Collide(TM) and Collide App Designer(TM) platforms that enable businesses wishing to take advantage of growing trends in the internet-of-things, big-data and multi-dimensional, real-time geospatial experiences.
ABC: 80.16 (+0.84)
(0)
(0)Scroll down for more posts ▼